Extended Paxlovid fails to ease long COVID symptoms in 959-person trial
A large-scale clinical trial involving 959 patients has found that the antiviral drug Paxlovid does not effectively treat long COVID symptoms compared to a placebo. The study, part of the NIH's RECOVER initiative, tested the drug's ability to reduce symptoms like cognitive dysfunction and exercise intolerance.
Why it matters
The results provide definitive evidence that a widely used COVID-19 treatment is not a viable solution for long COVID, redirecting future research efforts.
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: SHVETS production from Pexels Results from a clinical trial and published today in the journal Lancet Infectious Diseases show that the antiviral drug Paxlovid, commonly prescribed to treat acute COVID-19, does not affect long COVID symptoms compared with a placebo.
Long COVID is a chronic health condition that can occur after a SARS-CoV-2 infection and lasts for at least three months. This trial is part of the NIH's Researching COVID to Enhance Recovery (RECOVER) Initiative, a patient-centered, integrated, adaptive research network that aims to understand, diagnose, prevent and treat long COVID.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in